688426.SHG Jiangsu Cowin Biotech Co. Ltd. A
- Market cap
- CNY 1.99B
- P/E
- -
- P/B
- 1.48x
- ROE
- -5.3%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688426.SHG undervalued?
Graham numberThe Graham number of Jiangsu Cowin Biotech Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Cowin Biotech Co. Ltd. A fundamental analysis
No fundamental analysis for Jiangsu Cowin Biotech Co. Ltd. A yet.
Jiangsu Cowin Biotech Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Cowin Biotech Co. Ltd. A
Jiangsu CoWin Biotech Co., Ltd. engages in the research, development, sales, testing, and technology services of biological reagents in China. The company offers RT-PCR, PCR, multiplex PCR, and qPCR; collection, such as cfDNA, fecal DNA, saliva DNA, and urine DNA storage tube, as well as other collection products; cfDNA, genomic DNA, FFPE DNA extraction, and plasmid kit; molecular raw materials; quantitative analysis, RNA sequencing, adapter, purification magbeads, DNA seque…
Full company profileJiangsu Cowin Biotech Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Cowin Biotech Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 233M | 338M | 522M | 171M | 126M | 194M | 226M |
| Gross Profit | 180M | 245M | 365M | 111M | 70.4M | 87.9M | 110M |
| Operating Income | 125M | 142M | 195M | -105M | -156M | -120M | -71.3M |
| EBITDA | - | - | 221M | -57.7M | -124M | -71.0M | -76.7M |
| Net Income | 108M | 126M | 159M | -84.4M | -157M | -107M | -70.4M |
| EPS | 1.29 | 1.50 | 1.42 | -0.75 | -1.40 | -0.95 | -0.63 |
| Balance Sheet | |||||||
| Total Assets | 472M | 649M | 1.96B | 1.82B | 1.62B | 1.50B | 1.49B |
| Total Liabilities | 57.0M | 101M | 164M | 143M | 132M | 138M | 161M |
| Shareholders' Equity | 414M | 548M | 1.78B | 1.66B | 1.47B | 1.35B | 1.32B |
| Cash & Short-term Investments | 38.8M | 128M | 1.03B | 348M | 255M | 161M | 210M |
| Cash Flow | |||||||
| Operating Cash Flow | 109M | 145M | 107M | -11.7M | -113M | -59.0M | - |
| Capital Expenditure | 13.5M | 124M | 100M | 159M | 48.4M | 34.8M | 29.4M |
| Free Cash Flow | 95.4M | 20.1M | 6.99M | -171M | -162M | -93.8M | -86.2M |
| Ratios | |||||||
| ROE | 26.1% | 23.0% | 8.9% | -5.1% | -10.7% | -7.9% | -5.3% |
| ROA | 22.9% | 19.4% | 8.1% | -4.6% | -9.7% | -7.2% | -4.7% |
| Net Profit Margin | 46.4% | 37.2% | 30.5% | -49.3% | -124.9% | -55.5% | -31.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jiangsu Cowin Biotech Co. Ltd. A dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 12, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 257K | 0.00 | - |
| 2024 | CNY 3.90M | 0.03 | - |
| 2023 | CNY 50.7M | 0.45 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | CNY 32.6M | 0.39 | 30.1% |
| 2019 | CNY 139K | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 12, 2023.
Who owns Jiangsu Cowin Biotech Co. Ltd. A
- Insiders 67.18%
- Institutions 6.12%
- Public & others 26.70%
- Shares outstanding 112M
- Free float 111M
Jiangsu Cowin Biotech Co. Ltd. A company profile
- Company name
- Jiangsu Cowin Biotech Co. Ltd. A
- Ticker
- 688426.SHG
- ISIN
- CNE100005NM2
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 769
- Fiscal year end
- December
- Address
- No. 18, Zelan Road, Taizhou, China, 225311
- Phone
- 86 523 8620 1352
- Website
- cwbio.com
About Jiangsu Cowin Biotech Co. Ltd. A
Jiangsu CoWin Biotech Co., Ltd. engages in the research, development, sales, testing, and technology services of biological reagents in China. The company offers RT-PCR, PCR, multiplex PCR, and qPCR; collection, such as cfDNA, fecal DNA, saliva DNA, and urine DNA storage tube, as well as other collection products; cfDNA, genomic DNA, FFPE DNA extraction, and plasmid kit; molecular raw materials; quantitative analysis, RNA sequencing, adapter, purification magbeads, DNA sequencing, and single cells sequencing products; molecular cloning, such as cloning reagents; nucleic acid residue and contamination screening reagent; and other products. It also provides gene synthesis, gene fragment, and codon optimization services. The company's products and services are used in infectious disease, eugenics and good parenting, and oncology applications. The company was founded in 2007 and is headquartered in Taizhou, China.
Jiangsu Cowin Biotech Co. Ltd. A management
3- Dr. Chun Xiang WangGM & Chairman · born 1967
- Ms. Zhihua ZhuangDeputy GM & Director · born 1981
- Mr. Yubai QiDeputy GM, Board Secretary & Director · born 1981